Pfizer Expects FY24 Operational Revenue Growth of 8%-10% Including Seagen Contribution And Excluding Comirnaty And Paxlovid Revenues; 3%-5% Excluding Both Seagen Contribution and Comirnaty and Paxlovid Revenues
Portfolio Pulse from Benzinga Newsdesk
Pfizer forecasts operational revenue growth of 8%-10% for FY24, factoring in contributions from Seagen but excluding revenues from COVID-19 products Comirnaty and Paxlovid. Without Seagen's contribution, the growth estimate is 3%-5%, still excluding Comirnaty and Paxlovid.
December 13, 2023 | 11:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer anticipates a significant revenue increase in FY24, including Seagen's contribution but excluding its COVID-19 related products, suggesting a strong underlying business performance.
The projected revenue growth indicates a positive outlook for Pfizer's core business, even without its COVID-19 related products. This could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100